Immunitybio Inc
$ 7.10
-1.39%
12 Jun - close price
- Market Cap 7,436,213,000 USD
- Current Price $ 7.10
- High / Low $ 7.32 / 7.04
- Stock P/E N/A
- Book Value -0.83
- EPS -0.85
- Next Earning Report 2026-08-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.34 %
- ROE N/A %
- 52 Week High 12.43
- 52 Week Low 1.95
About
ImmunityBio, Inc., an immunotherapy company, develops a memory T-cell cancer vaccine to fight multiple types of tumors without the use of high-dose chemotherapy.
Analyst Target Price
$13.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-02-23 | 2025-11-04 | 2025-08-05 | 2025-05-12 | 2025-03-03 | 2024-11-12 | 2024-08-12 | 2024-05-09 | 2024-03-19 | 2023-11-08 | 2023-08-08 |
| Reported EPS | -0.08 | -0.06 | -0.07 | -0.1 | -0.15 | -0.08 | -0.12 | -0.2 | -0.2 | -0.38 | -0.19 | -0.32 |
| Estimated EPS | -0.07 | -0.1106 | -0.1 | -0.1 | -0.16 | -0.13 | -0.18 | -0.15 | -0.16 | -0.18 | -0.18 | -0.23 |
| Surprise | -0.01 | 0.0506 | 0.03 | 0 | 0.01 | 0.05 | 0.06 | -0.05 | -0.04 | -0.2 | -0.01 | -0.09 |
| Surprise Percentage | -14.2857% | 45.7505% | 30% | 0% | 6.25% | 38.4615% | 33.3333% | -33.3333% | -25% | -111.1111% | -5.5556% | -39.1304% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-04 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.09 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: IBRX
2026-06-12 13:40:11
This article analyzes the current sentiment among analysts regarding ImmunityBio, Inc. (NASDAQ:IBRX). It will explore whether the current consensus leans towards an optimistic outlook for the company's future performance. The piece likely delves into financial metrics, recent developments, and expert opinions to gauge this sentiment.
2026-06-12 10:40:11
ImmunityBio's ANKTIVA immunotherapy showed promising Phase 3 data at the ASCO Annual Meeting for advanced non-small cell lung cancer and bladder cancer, reinforcing its investment thesis of becoming a broad immunotherapy platform. With an FDA sBLA review for bladder cancer anticipated by January 2027, the company faces both significant growth projections—$1.2 billion revenue by 2029—and risks due to high cash burn and single-franchise concentration. Investors are encouraged to review comprehensive analyses of the company's financial health and potential risks alongside these positive clinical trial outcomes.
2026-06-11 19:10:26
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against ImmunityBio, Inc. (IMMP) for corporate wrongdoing. The firm encourages investors who purchased ImmunityBio securities before January 19, 2026, and still hold them, to contact them to assist with the investigation. The representation of investors in class actions is on a contingency fee basis.
2026-06-11 05:10:26
ImmunityBio (IBRX) director Wesley Clark has been granted 65,600 stock options with an exercise price of $7.25 per share, expiring on June 9, 2036. These options will vest 100% on the earlier of June 9, 2027, or the date immediately before the next annual stockholder meeting, contingent on his continued service. This transaction is an award, not an open-market purchase, and is part of the company’s 2025 Equity Incentive Plan.
2026-06-11 01:08:57
ImmunityBio, Inc. (NASDAQ: IBRX) is highlighted as one of 2026's best-performing growth stocks, following its presentations at the ASCO Annual Meeting. The company showcased research on its FDA-approved immunotherapy ANKTIVA, designed to activate immune cells against various solid tumors, indicating its potential in cancer care. ImmunityBio focuses on developing next-generation immunotherapies for cancer and infectious diseases.
2026-06-11 00:08:57
ImmunityBio director Wendel Bruce was granted 65,600 stock options with an exercise price of $7.25 per share. These options are part of his compensation, vest fully on the earlier of June 9, 2027, or before the next annual stockholder meeting, and expire on June 9, 2036. This transaction is a grant and not an open-market purchase or sale of shares.
